Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report sent to investors on Friday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 0.0 %

BTX stock opened at $0.21 on Friday. The stock has a market capitalization of $12.07 million, a P/E ratio of -0.51 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The firm has a 50-day moving average price of $1.63 and a 200-day moving average price of $1.92.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.